SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?


To: Candle stick who wrote (785)8/19/1998 9:26:00 AM
From: Wesley0428  Respond to of 947
 
Misonix Announces Final Fourth Quarter and Year End Results

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Aug. 19, 1998--Misonix, Inc. (NASDAQ:MSON) today reported net sales of $9,410,354 for the three months ended June 30, 1998, an increase of 55% over the $6,054,165 reported for the comparable period last year.

The Company recorded net income of $2,441,761 or $.37 per share on a diluted basis for the quarter ended June 30, 1998, compared to net income of $2,107,956, or $.33 per share on a diluted basis for the quarter ended June 30, 1997.

Net sales for the year ended June 30, 1998 increased to $26,764,332 from $17,560,041 in the corresponding period last year. The Company had net income of $5,328,381, or $.81 per share on a diluted basis for the year ended June 30, 1998 as compared to net income of $177,125, or $.03 per share on a diluted basis for the year ended June 30, 1997.

These outstanding results reflect continued strong demand for the Company's Ultrasonic Soft Tissue Aspirator and first year revenues from sales of the Company's Ultrasonic Surgical Device as well as continued growth of the Company's scientific and industrial products.

Dr. Librizzi, President, stated that he is "pleased with the continued strong growth of Misonix and looks forward to making inroads into the medical device marketplace through continued growth of existing products as well as acquiring and developing new medical devices".

Misonix, Inc. develops, manufactures and/or markets medical, scientific and industrial ultrasonic and air pollution control systems.

-0- *T

MISONIX, INC. AND SUBSIDIARIES

COMPARATIVE RESULTS

(000's omitted, except per share figures)

Three Months Ended Twelve Months Ended

June 30, June 30, 1998 1997 1998 1997

NET SALES $ 9,410 $ 6,054 $26,764 $17,560

COST OF GOODS SOLD 4,131 2,357 12,236 7,591

GROSS PROFIT 5,279 3,697 14,528 9,969

Selling general and

administrative expenses 2,126 1,588 7,407 5,492

Research and development 155 160 859 351

Non-cash compensation charge -- 185 -- 4,545

Total operating expenses 2,281 1,933 8,266 10,388

INCOME (LOSS) FROM OPERATIONS 2,998 1,764 6,262 (419)

OTHER INCOME 397 376 1,142 680

INCOME BEFORE MINORITY

INTEREST AND INCOME TAXES 3,395 2,140 7,404 261

Minority interest in net income of consolidated subsidiary (4) (9) (14) (32)

INCOME BEFORE INCOME TAXES 3,391 2,131 7,390 229

INCOME TAXES (949) (23) (2,062) (52)

NET INCOME 2,442 2,108 5,328 177

NET INCOME PER SHARE-BASIC $ .43 $ .37 $ .94 $ .04

NET INCOME PER SHARE-DILUTED $ .37 $ .33 $ .81 $ .03

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING 5,724 5,672 5,690 4,835

WEIGHTED AVERAGE COMMON SHARES AND SHARE EQUIVALENTS OUTSTANDING 6,573 6,477 6,562 5,202

*T

Forward Looking Statements: Statements in this news release looking forward in time are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties, including general economic conditions, delays and risks associated with the performance of contracts, consumer and industry acceptance, and regulatory risks.

CONTACT:

Misonix Inc., Farmingdale

Peter Gerstheimer

516/694-9555



To: Candle stick who wrote (785)8/19/1998 9:28:00 AM
From: Wesley0428  Read Replies (1) | Respond to of 947
 
My own personal estimates were for $8,425,000 Q4 revenue and $.27 EPS. I
never made these public because I didn't want to set unrealistically
high expectations. Obviously MSON blew away my numbers! And as far as I
know I have as good a handle on MSON numbers as anybody does, so this is
a real upside surprise.
BTW these numbers translate into $.31 EPS on a "fully taxed" basis vs.
$.21 last year Q4 on an equivalent basis, that's almost 50% growth year
over year, despite a bunch more shares outstanding.
ÿ